MARKET

ICPT

ICPT

Intercept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.03
+0.94
+2.00%
Opening 13:18 07/06 EDT
OPEN
47.70
PREV CLOSE
47.09
HIGH
49.00
LOW
46.89
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
125.00
52 WEEK LOW
44.50
MARKET CAP
1.58B
P/E (TTM)
-4.4793
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 23 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ICPT stock price target is 70.77 with a high estimate of 180.00 and a low estimate of 46.00.

EPS

ICPT News

More
Intercept Pharmaceuticals: Regulatory Snub Unsettles Liver Therapy Front-Runner
Seeking Alpha - Article · 1d ago
FDA Rejects Intercepts Liver Disease Drug, But This Analyst Still Anticipates Approval
TipRanks · 4d ago
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
Zacks · 5d ago
Should You Throw in the Towel on Intercept Pharmaceuticals After Its Big Setback?
Motley Fool · 5d ago
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
Business Wire · 5d ago
Heavy upside, catalysts ahead in liver disease space for Needham
Seeking Alpha - Article · 5d ago
Intercept Slumps as the FDA Issues CRL to NASH Candidate
Zacks · 6d ago
BMO Capital Downgrades Intercept Pharmaceuticals to Market Perform, Lowers Price Target to $52
BMO Capital analyst Matthew Luchini downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Outperform to Market Perform and lowers the price target from $107 to $52.
Benzinga · 6d ago

Industry

Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.98%

Hot Stocks

Symbol
Price
%Change

About ICPT

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
More

Webull offers kinds of Intercept Pharmaceuticals Inc stock information, including NASDAQ:ICPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICPT stock methods without spending real money on the virtual paper trading platform.